Bracco Diagnostics announced that the Food and Drug Administration (FDA) has lifted the contraindication for use of Lumason (sulfur hexafluoride lipid-type A microspheres) in patients with known or ...
“The label change implemented by FDA is reflective of both the extensive data on contrast agents and the well characterized and stable safety profile of DEFINITY, which has been used to perform more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results